The ISN’s new IgA Nephropathy Curriculum delivers timely, practice-focused insights to help you integrate emerging evidence into care and optimize outcomes. Access the curriculum at the ISN Academy The curriculum is organized into three core areas of IgAN: pathogenesis, treatment, and prediction. Each section features in-depth conversations with David Wheeler, Jonathan Barret, and Michelle O'Shaughnessy, conducted...
At WCN’26, the high-impact trials (HIT) and late-breaking clinical trials (LBCT) sessions will show you what matters most for patient care right now. From headline results to ongoing studies, attendees will gain insights to translate evidence into better clinical decisions. Adeera Levin, chair of both the ISN–Advancing Clinical Trials Committee and the WCN’26 LBCT Advisory Group, explains that these sessions highlight the clinical trials most impactful to kidney care professionals, “This helps...
Kidney International® Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy A phase 2a trial tested felzartamab, an anti-CD38 antibody, in 54 patients with IgA nephropathy. Patients received different doses of felzartamab or placebo over six months. Felzartamab reduced protein in the urine, with the strongest and longest-lasting effect seen...
Kidney International® KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) IgA nephropathy and IgA vasculitis are leading causes of kidney disease worldwide, but treatment approaches have long varied. The KDIGO 2025 guideline consolidates the latest evidence to provide updated recommendations on diagnosis, risk assessment, and therapies, aiming...
Kidney International® Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy Zigakibart, a humanized monoclonal antibody targeting A Proliferation-Inducing Ligand (APRIL), was tested in healthy volunteers and patients with IgA nephropathy (IgAN) in a Phase 1/2 trial with 100-week follow-up. The treatment was well tolerated and led...
Understanding and managing rare kidney diseases can be challenging, even for experienced nephrologists. The ISN Rare Kidney Diseases Toolkit offers concise, expert-led guidance to support timely recognition and informed decision-making in complex cases. Explore the ISN Rare Kidney Diseases Toolkit Focused, accessible, and clinically relevant The toolkit features practical resources on a range of rare conditions, with...
Kidney International® Treatment of patients with IgA nephropathy: a call for a new paradigm Current treatments for IgA nephropathy (IgAN), including supportive care and corticosteroids, have limited success and significant side effects. Advances in understanding IgAN’s pathogenesis have led to new targeted therapies and a proposed dual approach: targeting IgAN-specific mechanisms (e.g., pathogenic IgA production) and managing...
Watch the video here This video abstract was supported by Vera Therapeutics
This visual abstract was supported by Vera Therapeutics. Download Visual Abstract
The ISN has added two new webinars to its Rare Kidney Disease Toolkit, focusing on immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G). These expert-led sessions offer valuable insights into diagnosing, managing, and treating these rare but challenging kidney diseases. Watch "Advancements in C3 Glomerulopathy (C3G)," featuring David Kavanagh (UK), Alison Ma (Hong Kong), and...
Join Jonathan Barratt (UK) and Richard Lafayette (US) as they explore the challenges of treating patients with IgA nephropathy (IgAN), especially younger individuals. Listen here With new medications now available, navigating treatment options has become more complex. Professor Lafayette presents a compelling case study from his practice, highlighting the real-world challenges of managing IgAN. This podcast is...
ISN-ACT Global Trials Focus editorial team member Megan Borkum summarizes the design and outcomes of the latest ISN-ACT Global Trials Focus "Trial of the Month." The "Trial of the Month" is available in several languages, now including German. Read all global trial selections from the ISN-ACT initiative here. In addition, in the ISN 'Guide for Everyone' series, selected clinical trials...
Kidney International® Home Dialysis: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference In May 2021, KDIGO held a conference on expanding home dialysis emphasizing the need for policy alignment, resources, and shared decision-making between patients, care partners, and healthcare teams to improve access and use. The conference stressed the need to advocate for...
ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus's latest trial selections. Read all global trial selections from the ISN-ACT initiative here. The "trial of the month" is available in several languages. In addition, selected clinical trials are demystified for the layperson. Efficacy and safety...
Click on the image to expand This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis company.
ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design and outcomes of the team's latest "Trial of the Month." Stay updated on the latest research and developments in kidney care: Access the new selection of global trials from the ISN-ACT initiative here. The "Trial of the Month" is available in several languages. Sparsentan Versus Irbesartan...
The kidney is particularly susceptible to damage by complement. Activation of the complement system is tightly regulated by a series of soluble and membrane-bound proteins. Failure of these checking mechanisms is one of the major causes of complement-mediated kidney diseases. Evidence of specific complement activity has been identified in several kidney diseases, including IgA nephropathy,...
This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis Company.
Daniel O’Hara, ISN-ACT Global Trials Focus coordinator, summarizes the design and outcomes of the latest "Trial of the Month." Explore all the global trial selections for November and December here. The "Trial of the Month" is available in several languages. A Phase 2 Trial of Sibeprenlimab in Patients With IgA Nephropathy Mathur et al., N Engl J Med...
Kidney International® Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification This report proposes a two-step classification of membranous nephropathy (MN). Step one is identifying the target antigen based on a multistep algorithm. The second step is the search for a potential underlying disease or associated condition. The meeting consensus favored using an antigen-based...
